Control group will receive 1500 mg/day (three 500 mg tablets/day) of plcebo orally for 12 weeks.

2 trials

Sponsors

Vice-Chancellor for Research, Tehran University of Medical Sciences

Conditions

Ankylosing spondylitis. Ankylosing spondylitisRheumatoid Arthritis. Seropositive Rheumatoid Arthritis

Phase 2

The therapeutic effects of a-L-Guluronic acid in patients with ankylosing spondylitis

Active, not recruitingIRCT2016091813739N4

Vice-Chancellor for Research, Tehran University of Medical SciencesAnkylosing spondylitis. Ankylosing spondylitis

Start: 2016-11-05Target: 25Updated: 2018-02-22

The therapeutic effects of a-L-Guluronic acid in patients with Rheumatoid Arthritis

Active, not recruitingIRCT2016092813739N5

Vice-Chancellor for Research, Tehran University of Medical SciencesRheumatoid Arthritis. Seropositive Rheumatoid Arthritis

Start: 2016-11-05Target: 36Updated: 2018-02-22

Related Papers

Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients

Iranian Journal of Allergy Asthma and Immunology2020-01-078 citations

Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORγt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients

Immunopharmacology and Immunotoxicology2019-12-1912 citations

The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial.

2019-02-104 citations

Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.

2019-02-015 citations

A randomized clinical trial for the assessment of the efficacy and safety of guluronic acid (G2013) in patients with rheumatoid arthritis

Immunopharmacology and Immunotoxicology2019-01-0211 citations